TICKERNERD
Menu
STLNSTLNHealthcare · Medical Care Facilities

STLN Stock Forecast: Starling Oncology, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$6.37
−2.30% on the day

The 5 Wall Street analysts covering Starling Oncology, Inc. hold a median 12-month price target of $9 — +41.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 15 Sept 2026 — in the upper half.

Market cap
$664.5M
Ticker Nerd rank
65 / 100
Median analyst target
$9.00
Analysts covering
5
Revenue$161.3M+34.6% y/y
Operating income−$4.6M
Net income−$9.8M
Free cash flow$11.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
−1.2%
From high
−4.4%
From low
+33.5%
$4.77
$6.66
Range since 29 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

STLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Starling Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Momentum
93
Accruals
84
Size
50
Quality
50
Revisions
48
Value
32
Issuance
28
Volatility
27

Growth (94): Sales and profits are climbing, and climbing faster than before.

Volatility (27): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 29 July 2026Adjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00Aug 26Aug 26Aug 26Aug 26Aug 26Sep 26Sep 26STLNHigh $11.00Median $9.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $7.00Median $9.00High $11.00

The green dot is the last close — the median target sits +41.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026BTIGMaintainsBuy$8.00 → $9.00
9 July 2026BTIGMaintainsBuy—
6 July 2026Lake StreetInitiatesBuy$10
6 July 2026Lake StreetInitiatesBuy—
17 June 2026NeedhamMaintainsBuy—
8 June 2026BTIGMaintainsBuy—
13 Mar 2026B. Riley SecuritiesMaintainsBuy—
13 Mar 2026NeedhamReiteratesBuy—
9 Mar 2026BTIGReiteratesBuy—
9 Mar 2026NeedhamReiteratesBuy—
25 Nov 2025NeedhamInitiatesBuy—
21 Oct 2025BTIGReiteratesBuy—
16 July 2025B. Riley SecuritiesInitiatesBuy—
26 Feb 2024JefferiesAssumesBuy$2.50
16 June 2023GuggenheimMaintainsBuy—
20 Mar 2023GuggenheimMaintainsNeutral—
11 Nov 2022GuggenheimMaintainsBuy—
15 Aug 2022JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STLN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

STLN vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140Aug 26Aug 26Aug 26Aug 26Aug 26Sep 26Sep 26STLNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Starling Oncology, Inc. (STLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.0×

Cheaper than 94% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
−26.9×

Cheaper than 99% of US stocks

EV / EBITDA
−37.8×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
34.6%

Higher than 80% of US stocks

Earnings growth (YoY)
34.6%

Higher than 68% of US stocks

Gross margin
16.8%

Higher than 17% of US stocks

Operating margin
−2.9%

Higher than 29% of US stocks

Net margin
−6.2%

Higher than 23% of US stocks

Returns & dividend
Return on equity
320.0%

Higher than 99% of US stocks

Return on assets
−9.6%

Higher than 27% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Starling Oncology, Inc. (STLN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Starling Oncology, Inc. has a market value of $664.5M and an enterprise value of $728.2M.

  • Revenue in the twelve months to 30 June 2026: $587.2M. The latest quarter grew 34.6% year on year.

  • Net income over the same four quarters: −$36.3M, a −6.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.30.

  • Free cash flow in the twelve months to 30 June 2026: −$3.3M.

  • Shares outstanding: 100.5M.

  • Trailing P/E: −12.0×; forward P/E: 479.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Starling Oncology, Inc. employs 641 people — $916K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

STLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
STLNStarling Oncology, Inc.$664.5M
65
GMRSGMR Solutions, Inc.$687.6M
2
SRTAStrata Critical Medical, Inc.$456.9M
48
CYHCommunity Health Systems, Inc.$411.4M
69
AUNAAuna SA$381.9M
55
USPHU.S. Physical Therapy, Inc.$1.2B
53
AMNAMN Healthcare Services, Inc.$1.3B
100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Starling Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STLN news & analysis

Starling Oncology to Participate in Wells Fargo Healthcare Conference

GlobeNewsWire · 24 Aug 2026neutral

Starling Oncology announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the Wells Fargo Healthcare Conference in Boston on September 8, 2026, including a fireside chat from 4:30–5:05 p.m.

Why it matters — A STLN watcher would care because the company's top executives will present to investors at a major healthcare industry conference, offering visibility into the company.

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

GlobeNewsWire · 17 Aug 2026positive

Starling Oncology announced the launch of Starling Oncology Nexus, a proprietary technology platform designed to address NCCN compliance and streamline the fragmented, administratively burdensome prior authorization process for oncology providers. The company described Nexus as built to optimize provider engagement and accelerate high-quality care at scale.

Why it matters — STLN watchers would care because the launch introduces a proprietary technology offering that could support the company's value-based community oncology operations by easing administrative burdens and encouraging guideline compliance.

Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Starling Oncology, Inc. (STLN). The item consists solely of the headline announcing the release of this transcript.

Why it matters — A STLN watcher would care because the earnings call transcript provides the company's full commentary on its latest quarterly results and outlook.

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

The Oncology Institute, Inc. (STLN) reported a second-quarter loss of $0.08 per share, wider than the Zacks Consensus Estimate of a $0.07 loss but narrower than the $0.14 per-share loss from the same quarter a year ago. The company also surpassed revenue expectations for the quarter.

Why it matters — STLN watchers would care because the quarterly loss came in above the consensus estimate while revenue beat expectations, though the loss still exceeded analyst forecasts.

The Oncology Institute Rebrands as Starling Oncology

GlobeNewsWire · 3 Aug 2026neutral

The Oncology Institute, Inc., one of the largest value-based oncology groups in the United States, announced that it has rebranded to Starling Oncology, Inc.

Why it matters — A TOI watcher would care because the company's corporate identity is changing, which could affect how it is recognized and followed in the market.

FAQ

Frequently asked questions about STLN stock

What is the STLN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Starling Oncology, Inc. have a median 12-month price target of $9, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STLN stock a buy right now?

Of the 5 analysts covering Starling Oncology, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Starling Oncology, Inc. 65 out of 100 across roughly 4,600 US stocks as at 15 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STLN?

As at 15 Sept 2026, Starling Oncology, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will STLN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +41.3% from the last close, and Ticker Nerd's factor model ranks Starling Oncology, Inc. 65 out of 100 as at 15 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STLN stock forecast for 2030?

No analyst covering Starling Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.

What does Starling Oncology, Inc. do?

Starling Oncology Inc. is a healthcare company focused on delivering specialized, value-based cancer care through a community-based oncology platform.

What is the latest news on STLN?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Starling Oncology to Participate in Wells Fargo Healthcare Conference". Starling Oncology announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the Wells Fargo Healthcare Conference in Boston on September 8, 2026, including a fireside chat from 4:30–5:05 p.m.

Company

About Starling Oncology, Inc.

Starling Oncology Inc. is a healthcare company focused on delivering specialized, value-based cancer care through a community-based oncology platform. The company provides physician-led oncology services that include cancer diagnosis and treatment, in-house infusion, specialty pharmacy support, clinical trials, radiation oncology, transfusion services, and coordinated patient support. Its integrated model is designed to manage care across multiple touchpoints, helping patients navigate treatment with access to medication management, case coordination, and ongoing clinical assistance. Starling Oncology serves adult and senior cancer patients through clinics and affiliated care sites across several U.S. states, making it a significant provider in community oncology. The company’s current business is centered on combining advanced cancer therapies with accessible local care delivery for patients and payors.

CEO Dr. Daniel Virnich FACHE, M.B.A., M.D. · 641 employees · United States · https://starlingoncology.com